Alnylam Pharmaceuticals, the Cambridge, MA-based developer of drugs that work by inhibiting production of certain proteins, said today it has obtained key intellectual property for technology to do the opposite. The company (NASDAQ: [[ticker:ALNY]]) completed exclusive license agreements with the University of Texas Southwestern Medical Center, the University of California, San Francisco, and the Salk Institute for Biological Studies. Many human diseases are caused by low production of certain proteins, and the new technology, dubbed RNAa, could help by activating the genes that encode those proteins, said Alnylam CEO John Maraganore in a statement.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
